Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women

Gynecological Endocrinology

Volumn 26, Issue 4, 2010, Pages 275-280

  Raffone, Emanuela ^a   Rizzo, Pietro ^a   Benedetto, Vincenzo ^a  

^a G Martino Hospital   (Italy)

Author keywords

Metformin; Myo inositol; Ovulation induction

Indexed keywords

CHORIONIC GONADOTROPIN; FOLIC ACID; INOSITOL; INSULIN SENSITIZING AGENT; METFORMIN; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ANOVULATION; ARTICLE; DRUG EFFICACY; FEMALE; FEMALE INFERTILITY; HUMAN; LOW DRUG DOSE; LUTEAL PHASE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; TREATMENT DURATION;

ADULT; ANOVULATION; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; FERTILITY AGENTS, FEMALE; FOLIC ACID; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; INOSITOL; MENSTRUATION DISTURBANCES; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY RATE; YOUNG ADULT;

EID: 77949454235     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590903366996     Document Type: Article

References (33)

1. Franks S. Polycystic ovary syndrome. N Engl JMed 1995;333: 853-861.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47.
4. Broekmans FJ, Fauser BC. Diagnostic criteria for polycystic ovarian syndrome. Endocrine 2006;30:3-11.
5. Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-219.
6. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol 2003;46:325-340.
7. Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:803-812.
8. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-789.
9. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87:2013-2017.
10. Cattrall FR, Healy DL. Long-term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:803-812.
11. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
12. De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006;21:2252-2256.
13. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myoinositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary sindrome. Gynecol Endocrinol 2008;24:139-144.
14. Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, Nestler JE. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390-1397.
15. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Effect of D-chiroinositol in lean women with the polycystic ovary sindrome. Endocrinol Pract 2002;8:417-423.
16. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, luorno MJ, Nestler JE. Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300-305.
17. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591-1596.
18. Cheang KI, Nestler JE. Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? Reprod Biomed Online 2004;8:440-447. Review.
19. Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005;6:1012-1022.
20. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome.NEngl JMed1999;340:1314-1320.
21. Legro RS, Barnhart HR, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, et al. Cooperative Multicenter Reproductive MedicineNetwork. Clomiphene,metformin,orbothfor infetility in polycystic ovary syndrome.NEngl J Med 2007;356:551-566.
22. Pesant MH, Baillargeon JP. Ovulation induction in polycystic ovary syndrome - how do metformin and clomifene citrate compare? Nat Clin Pract Endocrinol Met 2007;7:512-513.
23. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-957.
24. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750-1754.
25. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700-703.
26. Papaleo E, De Santis L, Baillargeon JP, Zacchè M, Fusi F, Brigante C, Ferrari A. Comparison of Myo-inositol plus folic acid vs. clomiphene citrate for first-line treatment in women with polycystic ovary syndrome. Hum Reprod 2008; 23(Suppl 1):101.
27. Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutr Rev 2002;60:80-87.
28. Larner J. Mediators of postreceptor action of insulin. Am J Med 1983;74:38-51.
29. Larner J. Insulin-signaling mechanisms. Lessons from the old testament of glycogen metabolism and the new testament of molecular biology. Diabetes 1988;37:262-275.
30. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990;13:244-256.
31. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17:579-582.
32. Nestler JE. Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. Fertil Steril 2008;90:14-16.
33. Nestler JE Metformin for the Treatment of the Polycystic Ovary Syndrome. N Engl J Med 2008;358:47-54.